biotech news today obesity drugs glp-1 New oral could offer more options for weight loss Novartis, Alector, Merck, Alnylm, UniQure

The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept

Some of the ingredients in Peaka, like curcumin, show modest GLP-1 stimulating effects in animal studies

Therefore, incretin-based therapeutic intervention has focused on GLP-1

showed that high doses of tirzepatide induced a significant reduction in fasting triglyceride levels at 26 weeks vs

Request comprehensive metabolic panels every three to six months during treatment and every one to three months during and after tapering

Related: Wegovy, Ozempic & Medicare: What Agents Need to Know Now Why Life Insurance Companies Are Spooked Life insurance companies are dealing with what they call "mortality slippage" accidentally classifying someone as lower-risk than they actually are